Role of Porcine Fibrin Sealant in the Prevention of Cervical Anastomotic Leakage after Esophagectomy for Esophageal or Esophagogastric Junction Cancer (PLACE020): A Phase 2, Single-Arm, Prospective Study
Yaobin Lin,Yihuai Hu,Yan Huang,Kongjia Luo,Kexi Wang,Amos Éla Bella,Rencun Lai,Yi Li,Dongrong Situ,Shuyun Wu,Jiyang Chen,Ting Lin,Xavier Benoit D’Journo,Nuria M. Novoa,Alessandro Brunelli,Hiran C. Fernando,Robert J. Cerfolio,Mahmoud Ismail,Chris Zhiyi Zhang,Jianhua Fu,Hong Yang,AME Thoracic Surgery Collaborative Group
DOI: https://doi.org/10.2139/ssrn.3393726
2019-01-01
Abstract:Background: Surgery is the primary treatment for esophageal or esophagogastric junction cancer (EC or EJC), but anastomotic leakage (AL) remains problematic. The use of fibrin sealant (FS) may reduce the incidence of AL. We aimed to assess the efficacy and safety of the application of porcine FS in the prevention of cervical AL for patients with EC or EJC. Methods: In this phase 2, single-arm, prospective study, we recruited patients aged 18-80 years with resectable EC or EJC, clinically staged as T1-4aN0-3M0. An open or minimally invasive McKeown esophagectomy was performed with circular stapled anastomosis. After anastomosis, 2·5 ml of porcine FS was applied circumferentially. The primary endpoint was the proportion of patients with AL within 3 months. Findings: From Jun 4, 2018, to Dec 29, 2018, 57 patients were enrolled, including 47 patients with thoracic EC and five with EJC. At the data cutoff date (Mar 31, 2019), two (3·5%) of the 57 patients had developed cervical AL. One (1·8%) patient was diagnosed with gastric fistula. The incidence of anastomotic stricture and other major postoperative complications was 1·8% and 17·5%, respectively. The median time needed to initiate oral feeding after operation was eight days (IQR 7·0-9·0). No adverse events related to FS were recorded. No deaths occurred within 90 days after surgery. Interpretation: Perioperative sealing with porcine FS is safe and shows promise for the prevention of AL after esophagectomy in patients with resectable EC or EJC. Further phase 3 study is warranted. Trial Registration Number: This study is registered at ClinicalTrials.gov, number NCT03529266. Funding Statement: The study was supported in part by grants from the Fundamental Research Funds for the Central Universities [grant number: 17ykzd30], the National Natural Science Foundation of China [grant number: 81402003], and the Guangdong Esophageal Cancer Institute Science and Technology Program [grant number: M201601].Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: The study obtained the approval from the ethics committee at Sun Yat-sen University Cancer Center and was done according to the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.